Our team of experts specializes in treating children with Langerhans cell histiocytosis (LCH) and hemophagocytic lymphohistiocytosis (HLH). Both conditions affect the immune system, but they do so in different ways.
Learn more about the histiocytosis conditions we treat:
- Langerhans cell histiocytosis (LCH)
- Hemophagocytic lymphohistiocytosis (HLH)
- Rare histiocytic disorders
Read "Histiocytosis: Still Rare, No Longer Obscure" on the histiocytosis and immune dysregulation treatment team, featured in the Winter 2018 issue of Promise magazine.
Histiocytosis and immune dysregulation treatment team
The histiocytosis and immune dysregulation treatment team includes specialists in oncology, infectious diseases, critical care and bone marrow transplant. These experts work together to craft a unique treatment approach for each child.
Meet your histiocystosis and immune dysregulation treatment team>
Highlight on histiocytosis research
St. Jude is the coordinating center for the North American Consortium for Histiocytosis (NACHO), a network of hospitals that provides support for histiocytosis clinical trials. NACHO's member hospitals work together to develop and test new treatments for histiocytic disorders. St. Jude patients who qualify can take part in NACHO clinical trials.